In agreement with our findings, Fox et al. showed that treatment with the dual IGF-IR/InsR inhibitor, AZD9362, enhanced the anti-tumor effect of the AKT inhibitor, AZD5363, in ER-positive breast cancer cells [76], indicating that the IGF axis plays a role in maintaining survival signaling pathways and limiting the efficacy of PI3K and AKT inhibitors. The gene discussed is IGF1; the disease is neoplasm.